Poolbeg Pharma PLC (LON:POLB) is analysed by Proactive Research Analyst Robin Davison on its first day of dealings on AIM after being spun out from Open Orphan PLC (LON:ORPH).
The firm has come to the market with an oversubscribed £25mln IPO.
As Davidson explains, Poolbeg plans to develop a potential treatment for influenza and is aiming for a near-term partnership with big pharma.
Click here to read Proactive's initiation report on 'Poolbeg Pharma: Trading now underway'